Form 4: Phio Pharmaceuticals Director Acquires Shares Through Restricted Stock Unit Vesting

Director Jonathan E. Freeman acquired 1,000 shares of Phio Pharmaceuticals Corp. through the vesting of a restricted stock unit on September 11, 2024.

Summary

• On September 11, 2024, Jonathan E. Freeman, a director of Phio Pharmaceuticals Corp., acquired 1,000 shares of common stock.
• The acquisition was a result of a restricted stock unit vesting.
• Following the transaction, Freeman directly owns 1,000 shares of Phio Pharmaceuticals Corp.
• Robert M. Infarinato, Attorney-in-Fact, signed the form on September 13, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of shares, which is a common occurrence in publicly traded companies.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Phio Pharmaceuticals, Director, Share Acquisition, Restricted Stock Unit, Form 4, Beneficial Ownership, Freeman, PHIO